Skip to content
Exclusive CEO Interviews

Press Release

Make us preferred on Google
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025

✨ Onyx Summary Lexicon Pharmaceuticals will present preclinical data at NeuPSIG 2025 showing pilavapadin (AAK1 inhibitor) reduced neuropathic pain in models of chemotherapy-induced peripheral neuropathy and multiple sclerosis, with a separate poster on the Phase 2b PROGRESS study design. The update broadens pilavapadin’s potential beyond diabetic peripheral neuropathic pain, aligning

Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer

Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer

✨ Onyx Summary Perspective Therapeutics has appointed Joel Sendek as Chief Financial Officer, effective immediately. Sendek, a veteran biotech finance executive with over $2.5 billion raised across prior CFO roles and a top-ranked equity research background, succeeds Juan Graham and is expected to strengthen the company’s financial and strategic

enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

✨ Onyx Summary ✨ Onyx Summary enGene Holdings announced it has reached target enrollment of 100 patients in the pivotal cohort of its Phase 2 LEGEND trial evaluating detalimogene voraplasmid in high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The company plans to overenroll the cohort and now anticipates submitting a Biologics License Application

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

✨ Onyx Summary Perspective Therapeutics has appointed Maya Martinez-Davis, President of GSK’s U.S. Commercial business, to its Board of Directors as an independent director. Martinez-Davis brings over two decades of biopharma leadership across GSK, Merck KGaA, and Pfizer, strengthening the company’s strategic and commercial expertise as it advances

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress

✨ Onyx Summary Lexicon reported a pooled post-hoc analysis of the SCORED and SOLOIST-WHF trials presented at ESC 2025 showing sotagliflozin reduced total CV death and HF events and lowered total MACE versus placebo consistently across age, including ≥65 and ≥75 years. The dataset (~12,000 participants; median age 69) supports

Seer Appoints Isaac Ro to its Board of Directors

Seer Appoints Isaac Ro to its Board of Directors

✨ Onyx Summary Seer, Inc. appointed Isaac Ro, Partner at Catalio Capital Management, to its Board of Directors, adding extensive financial and sector expertise in life science tools and diagnostics. Ro’s background in leading high-growth companies through IPOs, acquisitions, and strategic scaling strengthens Seer’s governance as it advances the

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

✨ Onyx Summary Keros Therapeutics announced that CEO Jasbir S. Seehra, Ph.D., will present at the Wells Fargo Healthcare Conference on September 4 and the H.C. Wainwright Global Investment Conference on September 9, 2025. The company will provide corporate and program updates, with presentation replays available for 90 days

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

✨ Onyx Summary Rocket Pharmaceuticals (NASDAQ: RCKT) will present at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences this September, spotlighting its late-stage genetic therapy pipeline for rare cardiovascular and hematologic disorders. With pivotal programs nearing key milestones, Rocket’s presence underscores its transition toward commercialization—an inflection point closely

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

✨ Onyx Summary Kyverna Therapeutics hosted a virtual KOL event outlining progress in its neuroimmunology CAR T franchise, including updated compassionate use data and details of its FDA-aligned Phase 3 trial design for KYV-101 in myasthenia gravis. The registrational KYSA-6 study, enrolling by year-end 2025, will evaluate KYV-101 against standard-of-care to

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences

✨ Onyx Summary Lexicon Pharmaceuticals announced that management will participate in fireside chats at Citi’s Biopharma Back to School Conference on September 3, 2025, and the H.C. Wainwright Global Investment Conference on September 8, 2025, with live webcasts available on the company’s investor site. The events provide Lexicon

Recursion to Participate in Upcoming Investor Conferences

Recursion to Participate in Upcoming Investor Conferences

✨ Onyx Summary Recursion Pharmaceuticals announced participation in two upcoming investor conferences: the Citi 2025 BioPharma Back to School Conference on September 3, 2025, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025. The company’s engagement underscores its strategy to highlight progress in scaling its Recursion

Belite Bio to Participate in Three Upcoming Investor Conferences

Belite Bio to Participate in Three Upcoming Investor Conferences

✨ Onyx Summary Belite Bio announced that its executive team will present at three major upcoming investor conferences in early September, including Cantor, Morgan Stanley, and H.C. Wainwright. Each presentation will be webcast and available for replay on the company’s investor relations website. These appearances highlight growing investor interest

enGene to Participate in Upcoming Investor Conferences

enGene to Participate in Upcoming Investor Conferences

✨ Onyx Summary enGene Holdings announced its participation in three upcoming investor conferences in September 2025, including the Wells Fargo Healthcare, H.C. Wainwright Global Investment, and Morgan Stanley Global Healthcare conferences. Management will present company updates and discuss progress on detalimogene voraplasmid, its lead non-viral gene therapy candidate for high-risk

Geron to Participate in the 2025 Wells Fargo Healthcare Conference

Geron to Participate in the 2025 Wells Fargo Healthcare Conference

✨ Onyx Summary Geron Corporation announced it will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference in Boston on September 4, 2025, with a live webcast accessible on its investor website. The appearance highlights Geron’s investor engagement strategy as it advances commercialization of RYTELO® and progresses